CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207. A total of 11 filers reported holding CITIUS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,847 | -52.5% | 103,577 | -16.7% | 0.00% | – |
| Q2 2023 | $149,170 | +648465.2% | 124,308 | +621440.0% | 0.00% | – |
| Q1 2023 | $23 | -81.1% | 20 | -87.1% | 0.00% | – |
| Q4 2022 | $122 | – | 155 | +7650.0% | 0.00% | – |
| Q3 2022 | $0 | – | 2 | -96.3% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 54 | -99.7% | 0.00% | – |
| Q1 2022 | $32,000 | -80.2% | 18,016 | -82.9% | 0.00% | – |
| Q4 2021 | $162,000 | +84.1% | 105,637 | +142.9% | 0.00% | – |
| Q3 2021 | $88,000 | -30.7% | 43,487 | +18.9% | 0.00% | – |
| Q2 2021 | $127,000 | +6250.0% | 36,564 | +2141.8% | 0.00% | – |
| Q4 2019 | $2,000 | -60.0% | 1,631 | -70.7% | 0.00% | – |
| Q3 2019 | $5,000 | +150.0% | 5,569 | +135.1% | 0.00% | – |
| Q2 2019 | $2,000 | – | 2,369 | +78866.7% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 3 | -99.9% | 0.00% | – |
| Q3 2018 | $6,000 | – | 3,437 | +171750.0% | 0.00% | – |
| Q2 2018 | $0 | – | 2 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Inspire Advisors, LLC | 196,867 | $181,000 | 0.05% |
| Wealth Advisory Solutions, LLC | 156,850 | $144,000 | 0.04% |
| Horst & Graben Wealth Management LLC | 75,722 | $70,000 | 0.02% |
| Ergoteles LLC | 451,890 | $416,000 | 0.01% |
| Miller Investment Management, LP | 50,000 | $46,000 | 0.01% |
| Virtu Financial LLC | 81,410 | $75,000 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 17,342 | $16,000 | 0.00% |
| Kestra Advisory Services, LLC | 71,102 | $65,000 | 0.00% |
| Csenge Advisory Group | 15,000 | $14,000 | 0.00% |
| Qube Research & Technologies Ltd | 121,281 | $112,000 | 0.00% |